arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

JOHNSON & JOHNSON

JNJ
$257.17 ▼ -0.41 (-0.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
75 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
76
Health
Good
Bullish
auto_awesome

Analytical Summary

JOHNSON & JOHNSON shows strong fundamentals with top-quartile Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $619.1B
Dividend Yield 0.52%
Revenue Growth 6.6%
Op. Margin None
ROIC None
FCF / Share $3.03
Trailing P/E 111.8x
Price / Book 7.3x
FCF Yield 1.2%
Debt / Equity 0.58
info Valuation on last close. End-of-day price, Aug 6, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$25.31B
↑ +6.6%
Net Income Profit after all expenses
$5.53B
— -0.1%
Operating Margin Operating profit as % of sales
33.5%
↓ -12.2%
FCF / Share Free cash flow per share
$3.03
↑ +398.2%
Long-Term Debt Long-term obligations
$37.34B
— -0.5%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
86
Cash Quality
50

Dividend History

Dividend / share · sourced from SEC filings
$5.14 Latest / share
+4.7% YoY
+5.8% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 75 quarters